SMIs play a central role in modern oncology, offering targeted inhibition of signaling proteins and pathways critical to tumor growth and survival.54 They effectively block RTKs, such as EGFR, mesenchymal-epithelial transition factor (MET), and vascular endothelial growth factor receptors (VEGFR), intracellular signaling mediators, such as MAPK kinase and PI3K, and apoptotic regulators, including B-cell lymphoma 2.55 However, challenges such as acquired resistance and toxicity limit their long-term success. The gene discussed is EGFR; the disease is neoplasm.